Medpace Holdings, Inc. $MEDP Shares Sold by Bessemer Group Inc.

Bessemer Group Inc. reduced its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 7.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 317,040 shares of the company’s stock after selling 24,877 shares during the quarter. Bessemer Group Inc.’s holdings in Medpace were worth $178,066,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Quent Capital LLC acquired a new stake in shares of Medpace during the 3rd quarter worth about $25,000. Optiver Holding B.V. acquired a new stake in shares of Medpace during the 3rd quarter worth about $27,000. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medpace during the 4th quarter worth about $30,000. Quarry LP acquired a new stake in shares of Medpace during the 3rd quarter worth about $35,000. Finally, Root Financial Partners LLC acquired a new stake in shares of Medpace during the 3rd quarter worth about $38,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Robert W. Baird decreased their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Leerink Partners decreased their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 11th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research note on Friday, February 13th. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Finally, Mizuho set a $582.00 price target on shares of Medpace in a research note on Wednesday, February 11th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Medpace presently has an average rating of “Hold” and an average price target of $467.08.

Insider Buying and Selling at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 20.50% of the stock is currently owned by insiders.

Medpace Price Performance

Shares of MEDP stock opened at $419.17 on Friday. The firm has a market cap of $11.97 billion, a P/E ratio of 26.35, a PEG ratio of 2.15 and a beta of 1.19. Medpace Holdings, Inc. has a 1-year low of $284.48 and a 1-year high of $628.92. The firm’s 50-day simple moving average is $464.69 and its 200-day simple moving average is $525.83.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company’s revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: One market commentary highlighted two reasons to watch Medpace, suggesting the company may still have attractive operating or valuation characteristics despite the legal overhang. 2 reasons to watch MEDP and 1 to stay cautious
• Positive Sentiment: A review of Medpace’s recent quarterly results noted the company had beat earnings and revenue expectations, which can support the stock by reinforcing underlying business strength. Reflecting On Drug Development Inputs & Services Stocks’ Q1 Earnings: Medpace (NASDAQ:MEDP)
• Neutral Sentiment: Several law firms, including Faruqi & Faruqi, Rosen, Schall, DJS Law Group, Levi & Korsinsky, and Bleichmar Fonti & Auld, issued lead-plaintiff reminders and lawsuit notices tied to Medpace’s alleged securities-law violations. These are mostly procedural updates, but they keep the stock in the news and may add uncertainty. MEDP INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Medpace (MEDP) Investors of Securities Class Action Deadline on June 8, 2026
• Neutral Sentiment: Rosen Law Firm and others reiterated the June 8, 2026 lead-plaintiff deadline for investors who bought MEDP during the class period, keeping the litigation process front and center but not adding new operational news. ROSEN, A LEADING AND RANKED FIRM, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MEDP
• Negative Sentiment: The biggest downside catalyst is the ongoing securities-fraud class action, with allegations that Medpace overstated growth projections and disclosures around cancellation rates. That kind of headline risk can hurt investor confidence and pressure the stock. Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.